Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Pipeline Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Biovista, Khondrion, Spark Therapeutics - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2016" drug pipelines to their offering.

The report provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects.

Key Topics Covered:

• The report provides a snapshot of the global therapeutic landscape of Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
• The report reviews pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics and enlists all their major and minor projects
• The report assesses Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)

Companies Mentioned:

• Alkeus Pharmaceuticals, Inc.
• Biovista Inc.
• GenSight Biologics S.A.
• Khondrion BV
• Spark Therapeutics, Inc.
• Stealth BioTherapeutics Inc.

For more information visit http://www.researchandmarkets.com/research/6bw6xq/lebers